KQ Labs opens accelerator programme and announces LifeArc as a strategic partner
KQ Labs is now accepting applications for its third cohort of companies. Early stage data-driven health companies…
Following the success of our neuroscience-focused ion channel drug discovery collaboration, we look forward to cont… https://t.co/29sXTbab5x
LifeArc backs 15 patient studies into ‘re-purposed’ therapies to fight coronavirus
£10m in grants mean patient enrolment can begin immediately
LifeArc and MRC partnership creates new £16m fund to establish Gene Therapy Innovation Hubs
Hubs aim to address challenges in progressing novel gene therapy research into early stage clinical trials
LifeArc provides £2m to the University of Edinburgh STOPCOVID initiative
LifeArc provides £2m to the STOPCOVID project, which aims to test existing and experimental drugs to find a treatment for COVID-19
LifeArc launches £10 million research fund to address the challenges of COVID-19
Today, LifeArc, a UK-based medical research charity, has created a £10 million fund to support research to…
LifeArc announces seed fund investment in start-up GyreOx
The funding will support a two-year programme to develop and automate GyreOx’s proprietary drug discovery platform, MACRO.
LifeArc boosts investment in Cambridge University spin-out PolyProx Therapeutics to advance new class of cancer medicines
The investment will help advance studies to validate polyproxin® molecules as potential drug candidates across a range of cancers.
LifeArc and Scottish Government Chief Scientist Office launch new funding scheme to boost translational research in Scotland
Funding aims to progress strong discovery science to a point where additional substantive funding could be secured.
LifeArc marks Rare Disease Day 2020 with a call for more translational research
Translational research can turn promising science into new treatments for those with rare diseases. It’s why we…